Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marco Gardinali is active.

Publication


Featured researches published by Marco Gardinali.


Annals of Internal Medicine | 1990

The Systemic Capillary Leak Syndrome: Appearance of Interleukin-2-Receptor-Positive Cells during Attacks

Marco Cicardi; Marco Gardinali; Giuliana Bisiani; Alberto Rosti; Paola Allavena; Angelo Agostoni

Recurrent hypovolemic shock due to leakage of plasma from the vascular space without an apparent cause was first described by Clarkson and colleagues (1) in 1960 and was subsequently characterized ...


Circulation | 1994

Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator

Angelo Agostoni; Marco Gardinali; Donatella Frangi; Cristina Cafaro; Luisa Conciato; Carlo Sponzilli; Alessandro Salvioni; Massimo Cugno; Marco Cicardi

BackgroundWe have previously shown that treatment with streptokinase induces abrupt complement activation and transient neutropenia in patients with acute myocardial infarction (AMI). The purpose of this study was to compare the effects of two different thrombolytic agents—streptokinase (SK) and recombinant tissue-type plasminogen activator (rTPA)—on activation of the complement and kinin systems in plasma of patients with AMI. Methods and ResultsForty-one patients with AMI who were eligible for thrombolytic therapy were studied. Twenty-three patients were treated with streptokinase (1.5 million IU IV over 60 minutes) and 18 were treated with rTPA (8 with bolus of 10 mg IV, followed by 50 mg infused over 60 minutes and then 40 mg infused over 120 minutes; 10 patients were administered rTPA and heparin according to the accelerated infusion protocol indicated by the GUSTO study). C4a and C3a were measured by radioimmunoassay, soluble terminal complement components (SC5b-9) and anti-SK IgG antibodies were measured by ELISA. Cleaved high molecular weight kininogen (HK) was quantitated in plasma by SDS-PAGE and immunoblotting analysis. C4a levels were significantly and similarly increased in both groups, whereas the levels of C3a and SC5b-9 after rTPA infusion were only slightly elevated and were significantly lower than after SK. No differences were observed between patients treated with slow or accelerated rTPA regimens. The titer of antibodies to SK was highly correlated with the levels of C3a and SC5b- 9, whereas a lesser correlation was observed with C4a. Treatment with rTPA did not induce the transient neutropenia observed after SK infusion. The cleavage products of HK were significantly greater after SK than after rTPA infusion. ConclusionsOur results show that both thrombolytic agents activate the classic complement pathway and that plasmin could be the common trigger for this phenomenon. A significant activation of the complement common pathway (from C3 to terminal components) was observed only with SK infusion and is attributable to the rapid formation of immunocomplexes between SK and anti-SK antibodies present in plasma as a consequence of previous streptococcal infections. The minimal activation of C5 component of the common pathway explains the absence of leukopenia in patients treated with rTPA. Cleavage of HK, larger after SK than after rTPA infusion, represents a condition enhancing the generation of bradykinin by kallikrein. The recent experimental data that indicate a damaging effect of complement activation on the infarcted zone and the contrasting favorable effect consequent to bradykinin formation raise some questions about the clinical importance of the different biological consequences of SK versus rTPA.


Allergy | 1983

C1 INH Concentrate in the Therapy of Hereditary Angioedema

L. Berciamaschini; Marco Cicardi; A. Tucci; Marco Gardinali; Donatella Frangi; C. Valle; Angelo Agostoni

Ten acute attacks were managed in nine patients with hereditary angioedema by means of the infusion of a C1 INH concentrate produced on large scale. No side effects were observed.


The Journal of Allergy and Clinical Immunology | 1997

Idiopathic capillary leak syndrome: Evidence of CD8-positive lymphocytes surrounding damaged endothelial cells ☆ ☆☆ ★

Marco Cicardi; Emilio Berti; Valentina Caputo; Ferdinando Radice; Marco Gardinali; Angelo Agostoni

Idiopathic capillary leak syndrome (ICLS) is a lethal disease characterized by recurrent fluid extravasation leading to hypovolemic shock underlaid by marked hemoconcentrat ion (hematocrit as high as 80%). 1 Only 30 patients with ICLS have been reported in the literature, and the pathogenesis remains unknown. Extravasation of intravascular fluid, with similar clinical symptoms, is also a well-known complication of systemic administration of recombinant (r)lL-2. 2 In this last condition, direct in vivo interaction between IL-2-activated cells (probably LAK cells) and endothel ium results in cytotoxicity to endothelial cells. 3 We previously provided evidence that cytokines participate in the pathogenesis of ICLS by demonstrating the appearance of IL-2 receptor-positive cells during attacks in a patient with this disease. 4 Now we have studied the pathology of the same patient, who died during an attack, and have found that in the skin there were perivascular infiltrates of CD8 lymphocytes surrounding damaged endothelial cells, a picture similar to that of r IL-2-dependen t capillary leak syndrome (CLS).


Circulation | 1994

Abrupt complement activation and transient neutropenia in patients with acute myocardial infarction treated with streptokinase.

Donatella Frangi; Marco Gardinali; Luisa Conciato; Cristina Cafaro; L Pozzoni; Angelo Agostoni

BACKGROUND Whether and to what extent complement is activated in acute myocardial infarction (AMI) and how it contributes to inflammation of the ischemic area are not yet clear. Fibrinolytic agents used for thrombolysis are known to activate complement in vitro and may contribute to its activation in vivo. The aim of this study was to measure the extent of complement activation in AMI patients, some treated and some not treated with streptokinase. In addition, because abrupt complement activation in vivo is usually associated with leukocyte margination, plugging of cells in the microcirculation, and hypotension, we correlated complement activation with leukocyte numbers and mean arterial pressure. METHODS AND RESULTS Forty AMI patients were studied: 20 were treated with streptokinase (1.5 million IU IV over 60 minutes), and 20 were not given any fibrinolytic agent. The extent and severity of AMI were not significantly different in both groups. Blood samples were drawn on arrival at the hospital, during streptokinase infusion, and then daily for 1 week. Time-matched samples were also drawn from patients not treated with streptokinase. We measured plasma levels of anaphylatoxin C4a, C3a, and C5a by radioimmunoassay and membrane attack complexes SC5b-9 by enzyme immunoassay. Leukocytes and arterial pressure also were measured when samples were obtained. C4a, C3a, and SC5b-9 levels increased about 10-fold (P < .0001) during infusion of streptokinase. There were no significant increases in complement catabolic products in AMI patients not treated with streptokinase. There was a significant transient leukopenia (mean +/- SEM, -29.5 +/- 7.0%; P = .001) and decreases in systolic and diastolic pressures (systolic, -29.3 +/- 3.2%, P < .0001; diastolic, -27.5 +/- 3.4%, P < .0001) after 15 minutes of streptokinase infusion in coincidence with the peak of anaphylatoxins in plasma. CONCLUSIONS Streptokinase treatment of AMI causes abrupt activation of the complement system, whereas no significant complement activation can be detected in plasma of AMI patients not treated with fibrinolytic agents. Complement activation causes a transient leukopenia, as reported for such other clinical conditions as dialysis and cardiopulmonary bypass, and possibly contributes to the hypotension observed during streptokinase treatment.


Immunopharmacology | 1999

Cardiopulmonary bypass increases plasma bradykinin concentrations.

Massimo Cugno; J Nussberger; Paolo Biglioli; M.G Giovagnoni; Marco Gardinali; Angelo Agostoni

An increase of bradykinin (BK) plasma levels together with the activation coagulation cascade, fibrinolysis, complement and cytokines was observed during cardiopulmonary bypass (CPB). Since the procedure of extracorporeal circulation completely excludes the lung, the major site of BK catabolism, our data suggest that a reduced catabolism could contribute to the increase of BK during CPB.


Clinical & Developmental Immunology | 2005

Polymorphism of the fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension.

Bianca Marasini; Roberta Cossutta; Carlo Selmi; Maria Rosa Pozzi; Marco Gardinali; Marco Massarotti; Maddalena Erario; L. Battaglioli; Maria Luisa Biondi

Fractalkine (FKN) and its receptor CX3CR1 are critical mediators in the vascular and tissue damage of several chronic diseases, including systemic sclerosis (SSc) and pulmonary arterial hypertension (PAH). Interestingly, the V249I and T280M genetic polymorphisms influence CX3CR1 expression and function. We investigated whether these polymorphisms are associated with PAH secondary to SSc. CX3CR1 genotypes were analyzed by PCR and sequencing in 76 patients with limited SSc and 204 healthy controls. PAH was defined by colorDoppler echocardiography. Homozygosity for 249II as well as the combined presence of 249II and 280MM were significantly more frequent in patients with SSc compared to controls (17 vs 6%, p = 0.0034 and 5 vs 1%, p = 0.0027, respectively). The 249I and 280M alleles were associated with PAH (odd ratio [OR] 2.2, 95% confidence interval [CI] 1.01-4.75, p = 0.028 and OR 7.37, 95%CI: 2.45-24.60, p = 0.0001, respectively). In conclusion, the increased frequencies of 249I and 280M CX3CR1 alleles in a subgroup of patients with SSc-associated PAH suggest a role for the fractalkine system in the pathogenesis of this condition. Further, the 249I allele might be associated with susceptibility to SSc.


The Journal of Allergy and Clinical Immunology | 1986

In vivo study of the complement system during infusion of radiographic contrast media

Marco Gardinali; Marco Cicardi; Donatella Frangi; Massimo Franzinelli; Filippo Gattoni; Carlo Uslenghi; Angelo Agostoni

It has been claimed that activation of the complement system may play a role in reaction to radiographic contrast media (RCM) infusion. In order to clarify the effects of RCM on the complement system, three different parameters (CH50, C3a, and C1 inhibitor) were measured in 20 patients undergoing intravenous pyelography for diagnostic purposes. We found no significant changes in C3a levels, but CH50 and C1 inhibitor fell significantly at the different sampling times; however, the decreases lost significance when the data were corrected for hemodilution with the total protein content of each sample as a reference. We conclude that RCM infusion does not activate the complement system.


International Journal of Artificial Organs | 1994

Complement activation in dialysis: effects on cytokines, lymphocyte activation and beta 2 microglobulin.

Marco Gardinali; Calcagno A; Conciato L; Angelo Agostoni; Rosti A; Cori P; Vozzo N; Moroni A; Anelli A; Zoni U

Anaphylatoxins generated by complement activation by filter membranes are present in plasma during hemodialysis (HD). In the presence of endotoxins which may contaminate the dialysate, they can trigger monocytes to produce interleukin-1 (IL-1) and tumor necrosis factor (TNF), with detrimental effects for the patients. We have investigated whether or not the use of complement activating (cuprophan) and non- (or less-) activating membranes (polysulfone, polymethylmethacrylate or polyacrylonitrile) per se influences cytokine levels in HD patients. Our results indicate that if a sterile bicarbonate solution is used as dialysate, there are no significant increases in IL-1, TNF, interleukin-2 (IL-2) and soluble IL-2 receptors (sIL-2r) throughout HD, even with cuprophan membranes. Moreover even a prolonged use of this membrane (three months) did not change pre-dialysis levels of cytokines and receptors. Use of complement activating membranes also does not influence β2 microglobulin levels.


International Journal of Artificial Organs | 1985

Studies of complement activation in ARDS patients treated by long-term extracorporeal CO2 removal.

Marco Gardinali; Marco Cicardi; Donatella Frangi; Bergamaschini L; Gallazzi M; Luciano Gattinoni; Angelo Agostoni

To investigate the role of complement activation in the adult respiratory distress syndrome (ARDS) and in the complications of extracorporeal circulation (ECC), several parameters (CH50, C3 split products, C3a, C5a, PMN aggregating activity, carboxypeptidase activity) of the complement profiles of 23 ARDS patients were measured. Twenty patients were treated by long-term extracorporeal support. Before connection to ECC, marked leukocytosis (18,250 ± 5,950) and significantly high plasma C3a levels (p < 0.005) were observed. After connection, C3a levels increased further, up to values eight times higher than the basal ones. The WBC count transiently decreased to 41% of prebypass levels after 15 minutes of ECC. At the same time C3 split products appeared and PMN aggregating activity was shown in 52% of the patients. C5a levels remained normal during bypass, even in two samples in which PMN aggregating activity was detected. Later decreases in CH50 titers (p < 0.001) and carboxypeptidase activity (p < 0.005) were observed. Complement activation was no longer evident after the 24th hour of bypass. We conclude that there is a low-degree complement activation in ARDS, and ECC is a further strong stimulus for complement activation. This phenomenon appears, however, to be self-limited.

Collaboration


Dive into the Marco Gardinali's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge